URGN vs ELTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
URGN Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to UroGen Pharma Ltd. Ordinary Shares (URGN) driven by superior Valuation, Momentum & Technical, Options & Structure while ELTX counters with relative strength in Growth & Margin. Fundamentally, URGN trades at 11.1x Forward P/E with -12.4% operating margin (+223.9% YoY revenue) versus ELTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, URGN sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against ELTX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | URGN Revenue | ELTX Revenue | URGN Op. Margin | ELTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -6842.2% | N/A | URGN |
| FY2019 | $0M | N/A | -608211.1% | N/A | URGN |
| FY2020 | $10M | $0M | -1074.2% | -1919.2% | URGN |
| FY2021 | $50M | $30M | -192.1% | -138.8% | ELTX |
| FY2022 | $60M | $0M | -122.8% | -1031.4% | URGN |
| FY2023 | $80M | N/A | -79.2% | N/A | URGN |
| FY2024 | $90M | N/A | -107.1% | N/A | URGN |
| FY2025 | $110M | N/A | -113.7% | N/A | URGN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | URGN | ELTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5B | $42.5M | Larger Scale | URGN |
| Trailing P/E Ratio Valuation | 14.6x | N/M | Lower Multiple | URGN |
| Forward P/E Ratio Valuation | 11.1x | N/M | Lower Multiple | URGN |
| Revenue Growth (YoY) Growth | +223.9% | +0.0% | Higher Growth | URGN |
| Operating Margin (TTM) Profitability | -12.4% | 0.0% | Higher Margin | ELTX |
| Net Profit Margin Profitability | -26.3% | 0.0% | Higher Margin | ELTX |
| Return on Equity (ROE) Capital Efficiency | -1481.3% | -315.3% | Higher ROE | ELTX |
| 52-Week Range Position Momentum | 32% ($16โ$51) | 1% ($1โ$16) | Stronger Trend | URGN |
| Beta / 30D Volatility Risk Regime | 1.24ฮฒ ยท 90% Vol | 0.41ฮฒ ยท 92% Vol | Lower Realized Risk | URGN |
| Unified Institutional Score Composite Signal | 62.7 / 100 (BUY) | 53.1 / 100 (HOLD) | Higher Composite | URGN |